JP5917394B2 - 病理学的タウタンパク質の免疫学的標的化方法 - Google Patents

病理学的タウタンパク質の免疫学的標的化方法 Download PDF

Info

Publication number
JP5917394B2
JP5917394B2 JP2012515141A JP2012515141A JP5917394B2 JP 5917394 B2 JP5917394 B2 JP 5917394B2 JP 2012515141 A JP2012515141 A JP 2012515141A JP 2012515141 A JP2012515141 A JP 2012515141A JP 5917394 B2 JP5917394 B2 JP 5917394B2
Authority
JP
Japan
Prior art keywords
tau
seq
amino acid
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012515141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012530055A (ja
JP2012530055A5 (enExample
Inventor
アイナー エム． シグルドソン
アイナー エム． シグルドソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University
Original Assignee
New York University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University filed Critical New York University
Publication of JP2012530055A publication Critical patent/JP2012530055A/ja
Publication of JP2012530055A5 publication Critical patent/JP2012530055A5/ja
Application granted granted Critical
Publication of JP5917394B2 publication Critical patent/JP5917394B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
JP2012515141A 2009-06-10 2010-06-10 病理学的タウタンパク質の免疫学的標的化方法 Active JP5917394B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18589509P 2009-06-10 2009-06-10
US61/185,895 2009-06-10
PCT/US2010/038184 WO2010144711A2 (en) 2009-06-10 2010-06-10 Immunological targeting of pathological tau proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015230384A Division JP6174667B2 (ja) 2009-06-10 2015-11-26 病理学的タウタンパク質の免疫学的標的化方法

Publications (3)

Publication Number Publication Date
JP2012530055A JP2012530055A (ja) 2012-11-29
JP2012530055A5 JP2012530055A5 (enExample) 2013-07-25
JP5917394B2 true JP5917394B2 (ja) 2016-05-11

Family

ID=43306616

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2012515141A Active JP5917394B2 (ja) 2009-06-10 2010-06-10 病理学的タウタンパク質の免疫学的標的化方法
JP2015230384A Active JP6174667B2 (ja) 2009-06-10 2015-11-26 病理学的タウタンパク質の免疫学的標的化方法
JP2017132595A Active JP6518727B2 (ja) 2009-06-10 2017-07-06 病理学的タウタンパク質の免疫学的標的化方法
JP2019080694A Active JP6795649B2 (ja) 2009-06-10 2019-04-22 病理学的タウタンパク質の免疫学的標的化方法
JP2020188406A Active JP7229980B2 (ja) 2009-06-10 2020-11-12 病理学的タウタンパク質の免疫学的標的化方法
JP2022159988A Active JP7539446B2 (ja) 2009-06-10 2022-10-04 病理学的タウタンパク質の免疫学的標的化方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2015230384A Active JP6174667B2 (ja) 2009-06-10 2015-11-26 病理学的タウタンパク質の免疫学的標的化方法
JP2017132595A Active JP6518727B2 (ja) 2009-06-10 2017-07-06 病理学的タウタンパク質の免疫学的標的化方法
JP2019080694A Active JP6795649B2 (ja) 2009-06-10 2019-04-22 病理学的タウタンパク質の免疫学的標的化方法
JP2020188406A Active JP7229980B2 (ja) 2009-06-10 2020-11-12 病理学的タウタンパク質の免疫学的標的化方法
JP2022159988A Active JP7539446B2 (ja) 2009-06-10 2022-10-04 病理学的タウタンパク質の免疫学的標的化方法

Country Status (7)

Country Link
US (4) US8748386B2 (enExample)
EP (3) EP4218794A3 (enExample)
JP (6) JP5917394B2 (enExample)
CN (2) CN102596221B (enExample)
CA (3) CA2765099A1 (enExample)
EA (1) EA032675B1 (enExample)
WO (1) WO2010144711A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016094426A (ja) * 2009-06-10 2016-05-26 ニューヨーク・ユニバーシティ 病理学的タウタンパク質の免疫学的標的化方法

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090142766A1 (en) * 2007-11-09 2009-06-04 Washington University In St. Louis Methods for measuring the metabolism of cns derived biomolecules in vivo
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
CN102596236B (zh) * 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 抗原性Tau肽及其用途
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
WO2012045882A2 (en) * 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
AU2013205313B2 (en) * 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
LT2627672T (lt) * 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
WO2012106363A2 (en) * 2011-01-31 2012-08-09 Intellect Neurosciences Inc. Treatment of tauopathies
US8697076B2 (en) 2011-04-27 2014-04-15 Northwestern University Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies
GB201111361D0 (en) * 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
EP3275461A1 (en) * 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
JP6358953B2 (ja) * 2011-10-07 2018-07-18 エーシー イミューン エス．エー． タウを認識するホスホ特異的抗体
WO2013059786A1 (en) * 2011-10-21 2013-04-25 The Ohio State University Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease
CA2859665C (en) 2011-12-20 2024-05-21 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
CA2869438C (en) 2012-04-05 2021-08-17 Ac Immune S.A. Humanized tau antibody
TWI700296B (zh) * 2012-05-31 2020-08-01 公立大學法人大阪市立大學 失智症治療劑或預防劑
EP2870176A4 (en) * 2012-07-03 2016-09-28 Univ Washington ANTIBODIES DIRECTED AGAINST TAU
EP2885010B1 (en) 2012-08-16 2020-01-01 Ipierian, Inc. Methods of treating a tauopathy
US20140056901A1 (en) * 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
EP2887955B1 (en) 2012-08-21 2020-08-19 Institute for Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
US12024568B2 (en) 2012-09-13 2024-07-02 Cornell University Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
US9200068B2 (en) * 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
JP6284548B2 (ja) * 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ヒト抗タウ抗体
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
WO2014165271A2 (en) * 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
MX374811B (es) 2013-03-15 2025-03-06 Ac Immune Sa Anticuerpos anti-tau y métodos de uso.
US20160355573A1 (en) * 2013-09-05 2016-12-08 Cornell University Gene therapy for alzheimer's and other neurodegenerative diseases and conditions
BR112016010454A2 (pt) * 2013-11-27 2017-12-05 Ipierian Inc métodos para tratar uma taupatia
JP2017505756A (ja) * 2013-12-13 2017-02-23 ザ ジェネラル ホスピタル コーポレイション 可溶性高分子量（ｈｍｗ）タウ種およびその用途
EP3105251A4 (en) * 2014-02-10 2017-11-15 Merck Sharp & Dohme Corp. Antibodies that bind to human tau and assay for quantifying human tau using the antibodies
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽，抗Tau抗体，及其使用方法
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
CA2952741A1 (en) 2014-06-26 2015-12-30 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
EP3166688B1 (en) * 2014-07-08 2024-08-21 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
BR112017006419A2 (pt) 2014-09-30 2017-12-19 Univ Washington medições cinéticas de tau
JP6979577B2 (ja) 2015-02-20 2021-12-15 アミロニクス アクティエボラーグ アルツハイマーａベータペプチド結合ポリペプチド
AR103713A1 (es) 2015-02-26 2017-05-31 Lilly Co Eli Anticuerpos contra tau y sus usos
WO2016154522A1 (en) * 2015-03-25 2016-09-29 Stc. Unm Immunotherapy compositions and methods for treatment of tauopathy and transgenic mouse
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
CA2991264C (en) 2015-07-06 2023-10-10 Ucb Biopharma Sprl Tau-binding antibodies
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
PT3334761T (pt) * 2015-08-13 2023-08-17 Univ New York Moléculas baseadas em anticorpo seletivo para o epítopo {p}ser404 da tau e os seus usos no diagnóstico e tratamento de tauopatias
US10988528B2 (en) 2015-08-13 2021-04-27 New York University Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
US11351234B2 (en) * 2015-10-22 2022-06-07 Immunotherapy Development Inc. DNA vaccine against amyloid-β and tau
MD3171174T2 (ro) 2015-11-20 2018-02-28 Geroa Diagnostics S L Lactoferină pentru utilizarea în diagnosticul sau prognosticul bolii Alzheimer
WO2017096049A1 (en) 2015-12-03 2017-06-08 The University Of North Carolina At Pembroke Materials for cathepsin b enhancement and methods of use
US10906964B2 (en) 2016-05-02 2021-02-02 Prothena Biosciences Limited Antibodies recognizing tau
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JP7029415B2 (ja) 2016-07-12 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 過リン酸化タウに特異的な抗体およびその使用方法
JP6949102B2 (ja) 2016-08-09 2021-10-13 イーライ リリー アンド カンパニー 併用療法
LT3532064T (lt) 2016-10-28 2020-09-25 H. Lundbeck A/S Kompleksiniai gydymai, apimantys imidazopirazonus, skirti psichiatrinių ir (arba) kognityvinių sutrikimų gydymui
RU2019108717A (ru) 2016-10-28 2020-11-30 Х. Лундбекк А/С Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов
WO2018106889A1 (en) * 2016-12-09 2018-06-14 Cogwellin L.L.C. Diagnosis of alzheimer's disease
WO2018117647A1 (ko) * 2016-12-21 2018-06-28 주식회사 아델 변이된 타우 단백질 단편 및 이의 용도
US10995137B2 (en) 2017-01-04 2021-05-04 H. Lundbeck A/S Antibodies specific for hyperphosphorlated tau for the treatment of ocular diseases
CA3053379A1 (en) * 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
TWI771389B (zh) 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
EP3601325B1 (en) * 2017-03-28 2023-07-19 INSERM (Institut National de la Santé et de la Recherche Médicale) New tau species
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
TW202333768A (zh) 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
JP2021508673A (ja) 2017-10-27 2021-03-11 ユナイテッド ニューロサイエンスＵｎｉｔｅｄ Ｎｅｕｒｏｓｃｉｅｎｃｅ タウペプチド免疫原構築物
RU2020118913A (ru) 2017-12-14 2022-01-14 Х. Лундбекк А/С (H. Lundbeck A/S) Виды комбинированного лечения, предусматривающего введение 1h-пиразолo[4,3-b]пиридинов
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
US11535611B2 (en) 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
TW201946654A (zh) 2018-03-05 2019-12-16 比利時商健生藥品公司 抗ＰＨＦ－Ｔａｕ抗體及其用途
WO2019171258A1 (en) * 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Assays to detect neurodegeneration
CN110548135B (zh) 2018-05-31 2023-06-06 长春百克生物科技股份公司 磷酸化多肽抗原疫苗及其制备方法和应用
EP3829634A1 (en) 2018-07-31 2021-06-09 Eli Lilly and Company Combination therapy
WO2020106598A1 (en) * 2018-11-19 2020-05-28 The Board Of Regents Of The University Of Texas System Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies
WO2020123492A1 (en) * 2018-12-10 2020-06-18 New York University Monoclonal antibodies targeting c-terminal region of phosphorylated tau
CN111323597A (zh) * 2018-12-14 2020-06-23 陈志成 用于检测受试者中mci和/或ad的方法、试剂盒及筛选化合物的方法
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
SG11202108312PA (en) * 2019-02-08 2021-08-30 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體
CN113874078B (zh) 2019-04-05 2025-05-06 Tauc3生物制品有限公司 抗tauc3抗体及其应用
MX2021012994A (es) 2019-04-24 2022-03-04 Janssen Pharmaceuticals Inc Administracion heterologa de vacunas tau.
GB201909393D0 (en) * 2019-06-28 2019-08-14 Gen2 Neuroscience Ltd Tau epitope and binding molecules
GB2585252A (en) 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
CN110317814A (zh) * 2019-07-19 2019-10-11 莫丁丁 β-淀粉样蛋白环状核糖核酸、多肽及其应用
JP2022547513A (ja) 2019-09-09 2022-11-14 アクソン ニューロサイエンス エスエー アルツハイマー病及び軽度認知障害のバイオマーカー及び治療
CN110684122B (zh) * 2019-10-29 2021-03-02 中国人民解放军军事科学院军事医学研究院 重组Tau表位嵌合多聚体抗原、其制备方法和应用
AU2021276401A1 (en) * 2020-05-19 2022-12-15 Othair Prothena Limited Multi-epitope vaccine for the treatment of Alzheimer's disease
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
CN116723856A (zh) 2020-06-25 2023-09-08 默沙东有限责任公司 靶向丝氨酸413处磷酸化的tau的高亲和力抗体
IL300346A (en) * 2020-08-07 2023-04-01 Prothena Biosciences Ltd TAU vaccine for the treatment of Alzheimer's disease
CN116472055A (zh) * 2020-08-07 2023-07-21 欧萨尔普罗席纳有限公司 治疗阿尔兹海默氏病的多表位疫苗
WO2022054795A1 (ja) * 2020-09-08 2022-03-17 国立大学法人大阪大学 リン酸化タウタンパク質を標的とする免疫原性組成物
KR20240042508A (ko) * 2021-08-12 2024-04-02 얀센 파마슈티칼즈, 인코포레이티드 지속적인 면역 반응을 유도하기 위한 인산화 타우 펩티드를 함유하는 리포솜
JP2025137899A (ja) * 2022-06-28 2025-09-25 大塚製薬株式会社 シヌクレイノパチーを判定するための方法
EP4729530A1 (en) * 2023-06-15 2026-04-22 Gemvax & Kael Co., Ltd. Novel peptide and use thereof
CN116948025B (zh) * 2023-09-14 2024-04-02 北京凯祥弘康生物科技有限公司 一种抗Tau蛋白的抗体
WO2026102093A1 (en) 2024-11-07 2026-05-15 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
DE69033710T2 (de) 1989-10-24 2001-06-13 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Sekretion vom mit Gamma-Interferon Signalpeptid gebundenen humänen Protein
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
JP2916297B2 (ja) * 1991-02-25 1999-07-05 三菱化学株式会社 ホスホペプチド
WO1993003369A1 (en) 1991-08-01 1993-02-18 Voorheis Paul H Diagnostic method for alzheimer's disease
FR2681786A1 (fr) 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
ATE154642T1 (de) 1991-10-25 1997-07-15 Innogenetics Nv Monoklonale antikörper gegen das mikrotubulusassoziierte protein tau.
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
WO1993011231A1 (en) * 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US6010913A (en) * 1992-12-14 2000-01-04 N.V. Innogenetics S.A. Isolated human tau peptide
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
CA2163860A1 (en) 1993-06-30 1995-01-12 Chung C. Hsu Method for preparing liposomes
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
CA2203809C (en) 1994-10-28 2008-06-03 James M. Wilson Recombinant adenovirus and methods of use thereof
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
AU726544B2 (en) 1995-12-08 2000-11-09 University Of Alabama At Birmingham Research Foundation, The Targeted adenovirus vectors
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
ATE286072T1 (de) 2000-05-22 2005-01-15 Univ New York Synthetische immunogene jedoch nicht amyloidogene peptide, die homolog zu amyloid beta sind und deren verwendung zur induktion einer immunantwort gegen amyloid beta und amyloidaggregate
DE60128138T2 (de) 2000-11-02 2008-01-03 Cornell Research Foundation, Inc. In vivo multiphoton diagnostische detektion und bilddarstellung einer neurodegenerativen erkrankung
US20030104402A1 (en) 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
WO2002094191A2 (en) 2001-05-23 2002-11-28 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US20020197258A1 (en) 2001-06-22 2002-12-26 Ghanbari Hossein A. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
EP1572894B1 (en) 2001-11-21 2016-04-13 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto
GB0226727D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intrabodies
US20040247661A1 (en) 2002-07-03 2004-12-09 Dov Michaeli Liposomal vaccine
WO2004083431A1 (ja) * 2003-03-19 2004-09-30 Zoegene Corporation 転写反応を調節するタンパク質のスクリーニング方法および活性測定方法
WO2004087733A2 (en) 2003-03-28 2004-10-14 New York University Prevention and treatment of alzheimer amyloid deposition
US8685718B2 (en) 2003-05-20 2014-04-01 New York University Mucosal immunization to prevent prion infection
WO2006121656A2 (en) * 2005-05-05 2006-11-16 Merck & Co., Inc. Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
EP2077863A4 (en) 2006-10-31 2010-10-06 Domantis Ltd intrabodies
US20080220449A1 (en) 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
MX2011009654A (es) * 2009-03-18 2011-10-12 Ac Immune Sa Metodo para uso terapeutico.
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
EP4218794A3 (en) * 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
CN102596236B (zh) * 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 抗原性Tau肽及其用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016094426A (ja) * 2009-06-10 2016-05-26 ニューヨーク・ユニバーシティ 病理学的タウタンパク質の免疫学的標的化方法

Also Published As

Publication number Publication date
US8748386B2 (en) 2014-06-10
JP2019163268A (ja) 2019-09-26
US20170183400A1 (en) 2017-06-29
EP2440234A2 (en) 2012-04-18
JP7229980B2 (ja) 2023-02-28
JP6795649B2 (ja) 2020-12-02
JP2021042219A (ja) 2021-03-18
JP2012530055A (ja) 2012-11-29
JP2016094426A (ja) 2016-05-26
US11787854B2 (en) 2023-10-17
JP2022180615A (ja) 2022-12-06
EP3329932A1 (en) 2018-06-06
JP6518727B2 (ja) 2019-05-22
CN102596221B (zh) 2019-06-04
US20210061894A1 (en) 2021-03-04
CA3120504A1 (en) 2010-12-16
US20140302046A1 (en) 2014-10-09
WO2010144711A2 (en) 2010-12-16
EA032675B1 (ru) 2019-07-31
EP4218794A3 (en) 2023-09-13
JP2017193571A (ja) 2017-10-26
WO2010144711A3 (en) 2011-05-26
CN106390107B (zh) 2019-12-31
JP7539446B2 (ja) 2024-08-23
CA2765099A1 (en) 2010-12-16
EA201171397A1 (ru) 2012-05-30
EP4218794A2 (en) 2023-08-02
EP2440234A4 (en) 2013-11-06
US20100316564A1 (en) 2010-12-16
JP6174667B2 (ja) 2017-08-02
CN106390107A (zh) 2017-02-15
CA3239368A1 (en) 2010-12-16
CN102596221A (zh) 2012-07-18

Similar Documents

Publication Publication Date Title
JP7539446B2 (ja) 病理学的タウタンパク質の免疫学的標的化方法
US10253070B2 (en) Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
ES2434732T3 (es) Anticuerpos para beta-amiloide humanizados para su uso en mejorar la cognición
US20230130218A1 (en) Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
US20110200609A1 (en) Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence
JP2012041338A (ja) Ｓｙｎｕｃｌｅｉｎ病の予防および治療
CN103502272A (zh) 识别Tau的磷酸化特异抗体
HK40100443A (en) Immunological targeting of pathological tau proteins
HK1234334B (en) Immunological targeting of pathological tau proteins
HK1256470A1 (en) Immunological targeting of pathological tau proteins
HK1234334A1 (en) Immunological targeting of pathological tau proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140717

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141008

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150116

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150515

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151216

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160406

R150 Certificate of patent or registration of utility model

Ref document number: 5917394

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250